Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Opening Session Panel Discussion

Advertisement

Advertisement




Mar
18
Today In Oncology
Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer
Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
Women More Likely to Survive Cancer—But Suffer More Severe Side Effects
Forgotten Lessons From South Africa
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo